Symbols

KLRS

Kalaris·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About KLRS

Kalaris Therapeutics, Inc.

A late-clinical stage allogeneic T-cell immunotherapy company that develops allogeneic, off-the-shelf VST therapies for devastating viral diseases

Industry

Biological Technology

Established Date

08/16/2013

Listing Date

07/30/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.kalaristx.com

Security Type

Common stock

Office address

400 Connell Drive, Suite 5500, Berkeley Heights, New Jersey

Business

Introduction

Kalaris Therapeutics, Inc., established on August 16, 2013, is a Delaware limited liability company. The Company is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for common retinal diseases with serious unmet medical needs. The Company is developing TH103, a novel clinical-stage anti-vascular endothelial growth factor (" VEGF ") drug specifically designed to achieve prolonged intraocular retention and enhanced VEGF inhibition in patients with exudative and neovascular retinal diseases.

Company Financials

EPS

KLRS has released its 2025 Q4 earnings. EPS was reported at -0.53, versus the expected -0.59, beating expectations. The chart below visualizes how KLRS has performed over recent quarters, highlighting trends in earnings surprises.